Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01316055 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment
A Phase 1 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT01316055 is a Phase 1 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 42 participants.
The verdict
NCT01316055, a Phase 1 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The steady-state pharmacokinetics of Dalfampridine-ER (extended release) 7.5 mg (milligram) tablets in healthy adult volunteers and those with mild and moderate renal impairment, and examine between group comparisons.
Interventions
- DRUG Dalfampridine-ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01316055
The ClinicalTrials.gov registry entry for NCT01316055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dalfampridine-ER is the first listed.
NCT01316055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01316055 about?
NCT01316055 is a clinical study titled "Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment". The steady-state pharmacokinetics of Dalfampridine-ER (extended release) 7.5 mg (milligram) tablets in healthy adult volunteers and those with mild and moderate renal impairment, and examine between group comparisons.
What is the current status of trial NCT01316055?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2011-01. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01316055?
The interventions under investigation include: Dalfampridine-ER (DRUG).
Who is sponsoring clinical trial NCT01316055?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.